Bayer CropScience Gestion
Gestion contrôle des critères 2/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Simon-Thorsten Wiebusch
Directeur général
₹87.5m
Rémunération totale
| Pourcentage du salaire du PDG | 82.06% |
| Durée du mandat du directeur général | 2.5yrs |
| Propriété du PDG | n/a |
| Durée moyenne d'occupation des postes de direction | 2.1yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 1.8yrs |
Mises à jour récentes de la gestion
Recent updates
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | ₹7b |
| Sep 30 2025 | n/a | n/a | ₹6b |
| Jun 30 2025 | n/a | n/a | ₹6b |
| Mar 31 2025 | ₹87m | ₹72m | ₹6b |
| Dec 31 2024 | n/a | n/a | ₹5b |
| Sep 30 2024 | n/a | n/a | ₹6b |
| Jun 30 2024 | n/a | n/a | ₹7b |
| Mar 31 2024 | ₹86m | ₹70m | ₹7b |
| Dec 31 2023 | n/a | n/a | ₹8b |
| Sep 30 2023 | n/a | n/a | ₹8b |
| Jun 30 2023 | n/a | n/a | ₹8b |
| Mar 31 2023 | ₹96m | ₹82m | ₹8b |
| Dec 31 2022 | n/a | n/a | ₹8b |
| Sep 30 2022 | n/a | n/a | ₹7b |
| Jun 30 2022 | n/a | n/a | ₹7b |
| Mar 31 2022 | ₹29m | ₹25m | ₹6b |
Rémunération vs marché: La rémunération totale de Simon-Thorsten ($USD 903.57K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Indian ($USD 467.87K ).
Rémunération et revenus: La rémunération de Simon-Thorsten a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Simon-Thorsten Wiebusch (49 yo)
Mr. Simon-Thorsten Wiebusch is Vice Chairman, Managing Director and Chief Executive Officer of Bayer CropScience Limited from November 1, 2023. Mr. Wiebusch was Whole-Time Director at Bayer CropScience Lim...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Vice Chairman | 2.5yrs | ₹87.47m | pas de données | |
| Whole-Time Executive Director & CFO | 1.2yrs | ₹3.74m | pas de données | |
| Company Secretary & Compliance Officer | 1.8yrs | pas de données | pas de données | |
| Country Division Head of the Pharmaceutical Division | 2.3yrs | pas de données | pas de données | |
| Country Group Mngr of Environmental Science for India | no data | ₹2.36m | pas de données |
Gestion expérimentée: L'équipe de direction de 506285 est considérée comme expérimentée (ancienneté moyenne 2.1 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Vice Chairman | 4.4yrs | ₹87.47m | pas de données | |
| Whole-Time Executive Director & CFO | 1.2yrs | ₹3.74m | pas de données | |
| Non-Executive Independent Chairman | 9.8yrs | ₹2.06m | pas de données | |
| Non-Executive Woman Independent Director | 1.8yrs | ₹660.00k | pas de données | |
| Additional Non-Executive Independent Director | less than a year | pas de données | pas de données | |
| Non-Executive Non-Independent Director | 6.7yrs | pas de données | pas de données | |
| Non-Executive Non-Independent Director | 1.2yrs | pas de données | pas de données |
Conseil d'administration expérimenté: Le conseil d'administration de la 506285 n'est pas considéré comme expérimenté ( 1.8 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 03:16 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bayer CropScience Limited est couverte par 26 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |